AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03487432 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Super High-Pressure NC PTCA Balloon (OPN NC)
Description: Strategy of Super High-Pressure NC PTCA Balloon (OPN NC) after unsuccessful lesion preparation with conventional NC balloon angioplasty.
Study NCT03487432 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scoring PTCA Balloon (NSE Alpha)
Description: Strategy of Scoring PTCA Balloon (NSE Alpha) after unsuccessful lesion preparation with conventional NC balloon angioplasty.
Study NCT00446004 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Imatinib Mesylate
Description: Dosage form: tablets Dosage: 400 mg Frequency \& duration: On an 18-day schedule, one dose administered once on day 1 and once on day 15 (2 doses total)
Study NCT00446004 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Omeprazole
Description: Dosage form: capsules Dosage: 40 mg Frequency: On an 18-day schedule, once daily day 10 through day 16 (for Arm A); or once daily day -4 through day 1 (for Arm B)
Study NCT03646097 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angio-PCI
Description: PCI only with angiography and without OCT findings
Study NCT03646097 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OCT-PCI
Description: PCI with OCT-measurements but no transfer of landingzone-markers to angiography
Study NCT03646097 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACR-PCI
Description: PCI with OCT-measurements and transfer of landingzone-markers to angiography
Study NCT00516516 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Carnitine
Description: L-Carnitine, 1g orally, twice daily
Study NCT00516516 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, similar in appearance to study tablets, given orally, twice daily.
Study NCT00996853 — intervention group
Intervention type: OTHER
Intervention: Safety follow up
Description: Collection of reactogenicity data from diary cards, reporting of medically-attended adverse events, reporting of serious adverse events and adverse events of special interest, reporting of pregnancy outcomes and fatalities.
Study NCT03262480 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: stroke volume optimization
Description: Hemodynamic variables including stroke volume (SV), stroke volume variation (SVV), stroke volume index (SVI), cardiac output (COP), cardiac index (CI), systemic vascular resistance (SVR), systemic vascular resistance index (SVRI), thoracic fluid content (TFC), corrected flow time (FTC), index of contractility (ICON), systolic time ratio (STR), oxygen delivery (DO2) and oxygen delivery index (DO2I) will be measured by Cardiac output non-invasive monitor (ICONTM, OSYPKA medical cardiotronic GMBH, Elixir, Germany). Heart rate (HR), mean arterial blood pressure (MAP), central venous pressure (CVP) and arterial oxygen saturation (Sao2) will be measured using HP monitor.~If mean arterial blood pressure(MAP) drops below 65 mmHg despite achievement of SVopt and CVPmax in both groups, a bolus dose of 5 mg ephedrine will be given and repeated as needed .Norepinephrine will be given for persistent hypotension.Dobutamine 5 mic/kg/min will be started if cardiac index less than 2.5 l/m2.
Study NCT03262480 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stroke volume optimization
Description: Hemodynamic variables including stroke volume (SV), stroke volume variation (SVV), stroke volume index (SVI), cardiac output (COP), cardiac index (CI), systemic vascular resistance (SVR), systemic vascular resistance index (SVRI), thoracic fluid content (TFC), corrected flow time (FTC), index of contractility (ICON), systolic time ratio (STR), oxygen delivery (DO2) and oxygen delivery index (DO2I) will be measured by Cardiac output non-invasive monitor (ICONTM, OSYPKA medical cardiotronic GMBH, Elixir, Germany). Heart rate (HR), mean arterial blood pressure (MAP), central venous pressure (CVP) and arterial oxygen saturation (Sao2) will be measured using HP monitor.~If mean arterial blood pressure(MAP) drops below 65 mmHg despite achievement of SVopt and CVPmax in both groups, a bolus dose of 5 mg ephedrine will be given and repeated as needed .Norepinephrine will be given for persistent hypotension.Dobutamine 5 mic/kg/min will be started if cardiac index less than 2.5 l/m2.
Study NCT00337480 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: education
Description: education of acute coronary syndrome patients, mostly about nicotinic weaning, weight loss and physical activity
Study NCT04129567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Humidified oxygen
Description: Delivering humidified oxygen at 15 liters per minute through the nose in a blinded fashion using a nasal cannula.
Study NCT04129567 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry oxygen
Description: Delivering dry oxygen at 15 liters per minute through the nose in a blinded fashion using a nasal cannula.
Study NCT04129567 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Humidified air
Description: Delivering humidified air at 15 liters per minute through the nose in a blinded fashion using a nasal cannula.
Study NCT04129567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry air
Description: Delivering dry air at 15 liters per minute through the nose in a blinded fashion using a nasal cannula.
Study NCT04416841 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan
Description: Participants would take 24-form simplified Tai Chi Chuan 1 hour/session, 3sessions/week for 24 weeks. There were 10 minutes warm-up, 40 minutes Tai Chi Chuan lesson and 10 minutes cool-down exercises in the Tai Chi Chuan training. Besides, they would also take standard diabetic care education 0.5hour/session, 2 sessions/month for 6 months.
Study NCT04416841 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitness Walking
Description: Participants would take fitness walking training 1 hour/session, 3sessions/week for 24 weeks. There were 10 minutes warm-up, 40 minutes fitness walking and 10 minutes cool-down exercises in the fitness walking training, the exercise intensity was 50% to 70% of the maximum heart rate. Besides, they would also take standard diabetic care education 0.5hour/session, 2 sessions/month for 6 months.
Study NCT04416841 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Diabetic Care Education
Description: Participants would take standard diabetic care education 0.5hour/session, 2 sessions/month for 6 months.
Study NCT03366077 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Probiotic
Study NCT03366077 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic
Description: Probiotic
Study NCT01088724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine, cyclophosphamide, doxorubicin, rituximab
Description: Fludarabine i.v.(30 mg/sqm/day,day 1,2,3); Cyclophosphamide i.v.(750 mg/sqm, day 1); Doxorubicin i.v.(30 mg/sqm, day 1); Rituximab i.v. (375 mg/sqm, day 4).
Study NCT00923572 — intervention group
Intervention type: DRUG
Intervention: EE30/DRSP (Yasmin, BAY86-5131)
Description: Patients in daily life clinical practice treatment receiving Yasmin according to indication on the label.
Study NCT01939418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Afinitor 5mg qd. po.
Study NCT01939418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: gemcitabine 800mg/m2 iv. D1 and D8 every 3 weeks
Study NCT01939418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: cisplatin 30mg/m2 iv. D1 and D8 every 3 weeks
Study NCT00633113 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MPPA
Description: - Medial Parapatellar Arthrotomy
Study NCT00633113 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SV
Description: - Subvastus Technique
Study NCT01260402 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resynchronization using a transeptal approach
Description: Cardiac resynchronization with one in the right ventricle and one in the left ventricle via a transeptal puncture.~Devices used for procedure : Medtronic C304 or 6227DEF, Nykanen RF Wire, RADI PressureWire
Study NCT01260402 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resynchronization using a coronary sinus approach
Description: Cardiac resynchronization with one in the right ventricle and one in the left ventricle via the coronary sinus.~Devices used for procedure : RADI PressureWire, routine catheters chosen by operator
Study NCT01881828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin (glucophage)
Description: The strength of each tablet will be 500 mg. Participants will build up to a daily dose over four weeks by taking one tablet per day for 7 days, one tablet twice daily for 7 days, one tablet in morning and 2 tablets at night for 7 days, and then 2 tablets in the morning and 2 tablets at night, daily throughout the remainder of the study treatment period.
Study NCT01881828 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: oral placebo
Study NCT00923793 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Titanium implant (CranioConstruct™)
Description: One to three weeks before operation the skull defect is well defined using Computer tomography. Based on these results the Titanium implant is ordered.
Study NCT00923793 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydroxylapatite (CustomBone)
Description: Six to eight weeks before operation the skull defect is well defined using Computer tomography. Based on these results the Hydroxylapatite implant is ordered.
Study NCT01930006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGCD265
Study NCT01369888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/m\^2, intravenous (IV) (in the vein) x 2 days
Study NCT01369888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)
Study NCT01369888 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes
Description: IV over 30 minutes on day 0
Study NCT01369888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-15
Description: IV over 30 minutes, daily for 10 days, starting 3-4 hours after the TIL infusion. (day 0 to day 9). Doses will be increased every 3-6 patients.
Study NCT00298558 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Training
Description: Memory, Reasoning, or Speed of Processing cognitive training interventions
Study NCT00298558 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training
Description: Memory, Reasoning, or Speed of Processing cognitive training interventions
Study NCT04045028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Administered by IV infusion at a fixed dose of 600 mg on Day 1 of each 21-day cycle (Q3W)
Study NCT04045028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab/rHuPH20
Description: Administered by SC injection 1800 mg/30,000 U rHuPH20 weekly for a total of 6 doses, then every 3 weeks for a total of 16 doses (first dose given at Week 7), then every 4 weeks from Week 55 onward until disease progression
Study NCT04045028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Administered for a total of 8 doses. Rituximab will be administered by IV infusion for the first dose at a dose of 375 mg/m\^2. After administration of at least one full infusion of IV rituximab, the SC formulation of rituximab (rituximab and rHuPH20) may be used for the remaining doses per institutional guidelines. SC rituximab will be administered at a dose of 1400 mg rituximab/23400 U rHuPH20 once weekly (QW).
Study NCT04045028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Administered by IV infusion at a fixed dose of 1200 mg Q3W
Study NCT02545088 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid Assistive Limb (HAL)
Description: Intensive gait training with Hybrid Assistive Limb (HAL) is performed 1 session/day, 3 days/week for 6 weeks and each session will not exceed 60 min of effective walking time with HAL. In addition, each session will include conventional gait training that will not exceed 30 min effective training time.
Study NCT02545088 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1st control group
Description: Conventional gait training performed 1 session/day, 3 days/week for 6 weeks that will not exceed 1h 30 min effective training time.
Study NCT02545088 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2nd control group
Description: The 2nd control group will not receive an intervention.
Study NCT04002102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OLP treatment
Description: Receive two open-label placebo pills twice a day after randomization. Will receive for 21 days and then stop. It will include educational materials and positive expectancy.
Study NCT04002102 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Remain in standard care after randomization and educational materials.
Study NCT04002102 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Expectancy Group
Description: Educational materials and positive expectancy orientation via Zoom or telephone
Study NCT04237116 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational Arm - secukinumab
Description: secukinumab 300mg s.c. weekly in first 4 weeks, followed by q4w up to Week 20; and placebo 300mg s.c. at weeks 13, 14 and 15 to maintain the blind
Study NCT04237116 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Arm - placebo
Description: placebo 300 mg s.c. weekly in first 4 weeks, followed by q4w up to Week 8; and secukinumab 300 mg s.c. weekly for 4 weeks starting at Week 12, followed by q4w up to Week 20
Study NCT01073111 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: zotarolimus-eluting stent (ENDEAVOR®)
Description: zotarolimus-eluting stent
Study NCT01073111 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sirolimus-eluting stents (CYPHER SELECT® PLUS)
Description: sirolimus-eluting stents
Study NCT01073111 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: everolimus-eluting stents (PROMUS®)
Description: everolimus-eluting stents
Study NCT01342016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus capsule
Description: oral
Study NCT01342016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus placebo
Description: oral
Study NCT01342016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leflunomide tablet
Description: oral
Study NCT01342016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leflunomide placebo
Description: oral
Study NCT01342016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: oral
Study NCT01342016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: oral
Study NCT02689037 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty and stenting
Description: Surgeons will plant stents after vascular angioplasty in target ICAS vessels within 5 days after randomization.
Study NCT02689037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin plus clopidogrel
Description: aspirin 100mg daily and clopidogrel 75mg daily for 90 days
Study NCT02689037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin plus clopidogrel
Description: aspirin 100mg daily and clopidogrel 75mg daily for 90 days
Study NCT05589467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DASH-FP
Description: Dash diet with only fried potatoes
Study NCT05589467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DASH-NFP
Description: Dash diet with only non-fried potatoes
Study NCT05589467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Dash diet with no potatoes
Study NCT02841904 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Confocal LASER Endomicroscopy
Description: Patients scheduled for bladder endoscopic surgery under general anesthesia are offered to be included in our study. The suspicious mucosal areas are marked then examined with CLE. Tissue samples are taken based on the usual standard criterias. The samples are evaluated microscopically and compared with the results of the CLE technique. A single surgeon performs all surgeries. Biopsies are anlysed by a pathologist from Herlev and Gentofte Hospital's Pathology Department, which is affiliated CLE- study.
Study NCT02841904 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Confocal LASER Endomicroscopy
Description: Patients scheduled for bladder endoscopic surgery under general anesthesia are offered to be included in our study. The suspicious mucosal areas are marked then examined with CLE. Tissue samples are taken based on the usual standard criterias. The samples are evaluated microscopically and compared with the results of the CLE technique. A single surgeon performs all surgeries. Biopsies are anlysed by a pathologist from Herlev and Gentofte Hospital's Pathology Department, which is affiliated CLE- study.
Study NCT03461588 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: free-breathing
Description: patients are irradiated to whole breast +- regional nodal areas with free-breathing technique after breast conserving surgery
Study NCT03461588 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: deep inspiratory breath-holding
Description: patients are irradiated to whole breast +- regional nodal areas with deep inspiratory breast-holding technique after breast conserving surgery
Study NCT04078906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: n3-LCPUFA enriched Intravenous Lipid Emulsion
Description: To start from D0 at 1g/kg/day and increase by 1 g/kg daily till reaching 3 g/kg/day.
Study NCT00721968 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glaucoma Stent Surgery (GTS400 Stent)
Description: ab interno trabecular bypass stent surgery
Study NCT00721968 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: cataract surgery alone
Description: Cataract surgery alone
Study NCT02930018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerinetide (NA-1), 2.6 mg/kg
Description: Single intravenous infusion of nerinetide over 10 ± 1 minutes
Study NCT02930018 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator: Placebo
Study NCT06592456 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chickenpox Vaccines
Description: The vaccines require reconstitution with the provided sterile water for injection nd should be shaken well before use. Each human dose (0.5 ml) contains at least 3.3 log PFU of VZV.
Study NCT06592456 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Chickenpox Vaccines
Description: The vaccines require reconstitution with the provided sterile water for injection nd should be shaken well before use. Each human dose (0.5 ml) contains at least 3.3 log PFU of VZV.
Study NCT03593746 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Physical training
Description: Type 2 diabetic patients will be subjected to different types of physical training (high intensity interval training or combined training).
Study NCT03593746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical training
Description: Type 2 diabetic patients will be subjected to different types of physical training (high intensity interval training or combined training).
Study NCT03593746 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Light-Emitting Diode (LED) therapy
Description: Type 2 diabetic patients will be subjected to Light-Emitting Diode (LED) therapy (active or sham).
Study NCT03593746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Light-Emitting Diode (LED) therapy
Description: Type 2 diabetic patients will be subjected to Light-Emitting Diode (LED) therapy (active or sham).
Study NCT02786394 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REACH
Description: REACH is a lifestyle intervention program which aims to reduce sedentary behaviour, increase physical activity, and increase strength and balance. The REACH program is comprised of six sessions which include evidence-based education, behaviour change theory, and activity instruction. REACH also teaches goal setting techniques, mindfulness, and encourages active community engagement. In this study we are running the REACH program for women aged 55 and older alongside a supplementary optional walking program run by SportMedBC.
Study NCT04259814 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech-language therapy (SLT)
Description: Age-appropriate play activities with speech-language pathologist (SLP) to elicit speech, using stimulation strategies including but not limited to recasts, expansion, parallel talk, interactive modeling, communication temptations, and phrase completions. Activities will include an age-appropriate story, pretend play (i.e., house with people, playing with a baby doll), an assembly task (i.e., building blocks, making pretend pizza), and a highly motivating, clinician-controlled activity (i.e., blowing bubbles, swing, pushing cars down a ramp).